Avalon Pharmaceuticals Inc.

David K. Bol, Ph.D. has served as Vice President of Pharmaceutical Development since April 2005. Dr. Bol joined Avalon in September 2002 as a Senior Scientific Director. Prior to joining Avalon, Dr. Bol worked at Bristol-Myers Squibb since 1996 and was Group Leader and Principal Scientist at Bristol-Myers Squibb since 2001. Prior to Bristol-Myers Squibb, Dr. Bol was a Faculty Research Associate in the Department of Carcinogenesis at the M.D. Anderson Cancer Center in Houston, Texas. Dr. Bol holds a Ph.D. in Molecular and Cell Biology from University of Maryland and a B.S. from The University of Rochester, New York. Alan G. Walton, Ph.D., D.Sc. is a co-founder of Avalon and has served as a member and Chairman of our board of directors since Avalon s inception in November 1999. Since 1987, Dr. Walton has been a general partner of Oxford Bioscience Partners, a venture capital firm investing in life sciences enterprises. Prior to joining Oxford Bioscience Partners, Dr. Walton was President and Chief Executive Officer of University Genetics Co. Dr. Walton serves on the board of directors of Alexandria Real Estate Equities, Inc., Acadia Pharmaceuticals, Inc. and Advanced Cell Technologies, Inc. He previously has served as the Chairman of the Board of Directors or as a Director for numerous private and public biotechnology companies, including Human Genome Sciences and Gene Logic Inc. He was a professor at Case Western Reserve University and Harvard Medical College from 1961 to 1981 and a member of President Carter s Technology Transfer Committee from 1976 to 1977. Dr. Walton holds a Ph.D. in Physical Chemistry, a D.Sc. in Biological Chemistry and a B.S. in Chemistry, each from the University of Nottingham and in 2005 received a honorary LLD degree in recognition of his lifetime achievement in life sciences, also from the University of Nottingham.

James H. Meade, Ph.D., has served as Vice President of Business Development since January 2004. Prior to joining Avalon, Dr. Meade was Senior Director of Global Licensing at Pharmacia Corporation from January 2001 to July 2003. Before joining Pharmacia Corporation, Dr. Meade held senior level positions in business development at Bayer Corporation, Chiron Corporation and Cetus Corporation. Dr. Meade holds a Ph.D. and M.S. in Molecular Biology from the University of Texas at Dallas and a B.A. from St. Anselm's College.

Alan G. Walton, Ph.D., D.Sc. is a co-founder of Avalon and has served as a member and Chairman of our board of directors since Avalon s inception in November 1999. Since 1987, Dr. Walton has been a general partner of Oxford Bioscience Partners, a venture capital firm investing in life sciences enterprises. Prior to joining Oxford Bioscience Partners, Dr. Walton was President and Chief Executive Officer of University Genetics Co. Dr. Walton serves on the board of directors of Alexandria Real Estate Equities, Inc., Acadia Pharmaceuticals, Inc. and Advanced Cell Technologies, Inc. He previously has served as the Chairman of the Board of Directors or as a Director for numerous private and public biotechnology companies, including Human Genome Sciences and Gene Logic Inc. He was a professor at Case Western Reserve University and Harvard Medical College from 1961 to 1981 and a member of President Carter s Technology Transfer Committee from 1976 to 1977. Dr. Walton holds a Ph.D. in Physical Chemistry, a D.Sc. in Biological Chemistry and a B.S. in Chemistry, each from the University of Nottingham and in 2005 received a honorary LLD degree in recognition of his lifetime achievement in life sciences, also from the University of Nottingham.

Bradley G. Lorimier is a co-founder of Avalon and has served as a member of our board of directors since December 1999. Since 1999, Mr. Lorimier has been an independent consultant to the pharmaceutical and biotechnology industries. Mr. Lorimier has served in leadership positions in both the pharmaceutical and biotechnology industries, including as Vice President of Licensing and Vice President of Corporate Development at Johnson & Johnson and as Senior Vice President and Director of Human Genome Sciences. He is currently on the board of directors for Invitrogen Corporation and was a director of Matrix Pharmaceutical, Inc. from December 1997 to March 2002. Mr. Lorimier received his B.S. from the University of Illinois in 1967.

Dr. Ebner is a Scientific Director at Avalon Pharmaceuticals. He received his undergraduate degree in Biology from the University of Regensburg and his doctorate in Microbiology and Genetics from the University of Osnabr ck, Germany, where he then served on the faculty of the Genetics department. In 1989, Dr. Ebner was awarded a research fellowship to work as a visiting scientific specialist at Genentech, Inc. in San Francisco. There, he identified and cloned the long elusive first type I TGF-b receptor. In the years following, he made a series of substantial contributions to the fields of cytokine biology, receptor-ligand interactions and intracellular trafficking, cell differentiation, early development and tissue repair, first at Genentech and then at the University of California, San Francisco and at Stanford University Medical School. Dr. Ebner became one of the most productive novel gene finders at Human Genome Sciences and discovered several proteins now in preclinical and clinical development, including such molecules as LIGHT, IL-17B and its receptor, BlyS and TR6. In 2000, he joined Avalon Pharmaceuticals where he was instrumental in the initiation of intramural and external research programs and contributed to corporate and scientific infrastructure development. Dr. Ebner is a frequently invited plenary speaker at national and international conferences and member of scientific advisory panels. He is the author of 37 original research publications, including several articles in Science magazine, and is the primary inventor on more than 100 patent applications. Dr. Ebner collaborated with Dr. Wong since 1989 at Genentech.

Dr. Royston is a Founding Managing Partner of Forward Ventures. Dr. Royston has been involved in the biotechnology industry in San Diego from its inception in 1978 with the founding of Hybritech, Inc. (later acquired by Eli Lilly) and with the founding of Idec Pharmaceuticals in 1986 (which later merged with Biogen). Dr. Royston has been instrumental in the formation, financing, and development of numerous successful public biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Combichem (acquired by DuPont); Corixa (acquired by GlaxoSmithKline); Favrille; Genesys Therapeutics (merged with Somatix and acquired by Cell Genesys); and Triangle Pharmaceuticals (acquired by Gilead). Currently, Dr. Royston is the founding Chairman of Targegen in San Diego, and was elected Chairman of Morphotek in Exton, PA. He also serves on the Board of Directors of Avalon Pharmaceuticals, and Favrille, where he was the founding Chairman. Dr. Royston was previously the Founding President and CEO of the Sidney Kimmel Cancer Center (1990-2000) and on the faculty of the medical school and cancer center of the University of California, San Diego (1977-1990). He received his B.A. (1967) and M.D. (1970) degrees from the Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.

Lester J. Kaplan, Ph.D. has served as a director of our company since November 1997. Dr. Kaplan was Executive Vice President and President, Research and Development at Allergan, Inc. from November 2003 to April 2004. Dr. Kaplan joined Allergan in 1983 and, prior to being appointed to Executive Vice President, was Corporate Vice President, Research and Development and Global BOTOX from June 1998 to November 2003. Dr. Kaplan was elected to Allergan's board of directors in 1994 and served in that capacity until April 2004. Dr. Kaplan is also a member of the board of Acucela Inc. and the National Neurovision Research Institute. Dr. Kaplan received a M.S. and Ph.D. in organic chemistry from the University of California, Los Angeles. Torsten Rasmussen has served as a director of our company since April 1998. Mr. Rasmussen has been President and CEO of Morgan Management ApS, a management advisory and consulting company, since 1997. Prior to founding Morgan Management ApS in 1997, Mr. Rasmussen held the position of Executive Vice President, Operations at the LEGO Group (LEGO A/S) in Denmark, since 1981. He currently serves as a board member in the capacity of chairman, deputy chairman or ordinary board member of a number of Danish companies of which the following are quoted on the Danish Stock Exchange: Coloplast A/S, Bang & Olufsen A/S, TK Development A/S, Vestas Wind Systems A/S and A/S Det Oestasiatiske Kompagni. Mr. Rasmussen holds an M.B.A. from IMD in Lausanne, Switzerland. Alan G. Walton, Ph.D., D.Sc. has served as a director of our company since March 2003. Dr. Walton joined Oxford Partners as a General Partner in 1987. In 1991, he founded Oxford Bioscience Partners and he is currently Senior Partner and Chairman of Oxford Bioscience Corporation. Previously, he was President and CEO of University Genetics Co., a public biotechnology company involved in technology transfer and seed investments in university-related projects. Prior to University Genetics, he taught at several institutions including Harvard Medical School, Indiana University and Case Western Reserve where he was Professor of Macromolecular Science and Director of the Laboratory for Biological Macromolecules. Dr. Walton serves on the Boards of Alexandria Real Estate Equities and Advanced Cell Technology, and is Chairman, as well as a Board member, of Avalon Pharmaceuticals and Psychiatric Genomics. He is also on the Board of Research!America, a philanthropic organization. Dr. Walton was a founder of Human Genome Sciences and GeneLogic and is the Founding Chairman of the Biotechnology Venture Investors Group. Dr. Walton received a Ph.D. in chemistry and a D.Sc. in biological chemistry from Nottingham University in England and in 2005 received an honorary LLD degree for his lifetime achievement in life sciences form Nottingham University. Uli Hacksell, Ph.D also serves as Chief Executive Officer and a member of the board of directors. For a description of his background, please see "Management Team."

Michael Kurman, M.D. is an independent consultant to the pharmaceutical, biotechnology and health care industries specializing in oncology and oncology drug development, with 24 years of experience. He received his B.S. in Biology from Syracuse University graduating summa cum laude and received his M.D. degree from Cornell University Medical College. Dr. Kurman started his career in the practice of oncology, during which he was an investigator on several oncology clinical trials. Since joining industry, he has held positions of progressively more responsibility in Janssen, Cytogen and US Bioscience, and was involved in the successful development or launch of four oncology products. Before starting his consultancy, Dr. Kurman was Vice President of Clinical Operations for Quintiles' Oncology Division. His primary interests are in early/late phase oncology clinical trial design and drug development, and in strategic portfolio management. In addition, he serves on the Scientific Advisory Boards of several companies and is on the Board of Directors of Avalon Pharmaceuticals. Dr. Kurman is board certified in Internal Medicine and Oncology, and did his oncology training at Mt. Sinai Hospital in New York.

Patrick Van Beneden has been a director of TorreyPines since 2003. Since 2001, Mr. Van Beneden has been Executive Vice President Life Sciences of GIMV N.V., a Belgian investment company, and he has held various positions with GIMV since 1985. Mr. Van Benden has served as a member of the board of directors for Avalon Pharmaceuticals since October 2001. Mr. Van Beneden holds a Masters Degree in Applied Economics from VLEKHO-Brussels.

Raymond J. Whitaker, Ph.D. has been responsible for startups of new businesses, mergers and acquisitions, product licensing and equity financings in a career spanning 31 years. Before joining EuclidSR Partners, Raymond spent seven years at S. R. One, Limited, SmithKline Beecham's venture investing arm. Prior to that, he was Director of Worldwide Business Development at SmithKline Beecham. His diverse experience also includes previous positions at Recordati SpA, Italy; Laboratoires Delagrange, France; and IDA, Ireland. Raymond received his Ph.D. in Biochemistry as well as his M.B.A. from the National University of Ireland, University College, Dublin.

Mr. Van Beneden has served as a member of our board of directors since October 2001. Mr. Van Beneden is currently Executive Vice President Life Sciences of GIMV N.V., a Belgian investment company. Mr. Van Beneden has served on the boards of Crucell, N.V., Pharming Group N.V., and Innogenetics. Mr. Van Beneden holds a Master's Degree in Applied Economics from VLEKHO-Brussels.

Dr. William A. Scott has extensive research and management experience in both biotechnology and large pharmaceutical companies. Bill was previously Chief Executive Officer of Physiome Sciences, Inc., a company whose mission is to help pharmaceutical companies develop better drugs faster through the use of biological simulations. Prior to that, he held various senior level positions at Bristol-Myers Squibb ( BMS ) including Senior Vice President, Exploratory and Drug Discovery Research at BMS Pharmaceutical Research Institute from 1990 through 1996. During this period, he oversaw the submission of over 70 new chemical entities for development as new therapeutic agents. He consults or serves as a member of the board of directors of several biotechnology companies, including serving on the boards of publicly-traded AtheroGenics, Inc., Deltagen, Inc. and Variagenics, Inc. Bill holds a B.S. in Chemistry from University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. He is also an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969.